Every value below carries the sentence it was read from.
114 sources stand behind the page.
Field
Value
Cited text
Known as
(val)ganciclovir
“A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention...” NCT03443869 ↗104
“Valganciclovir (900mg) will be administered orally twice/day or Ganciclovir (5 mg/kg) will be administered i.v. over 1 hour for 14 days for cycle 1 and for 7 days (up to...” NCT01419561 ↗
“The antiviral nucleoside drug, (val)ganciclovir (GCV), is effective only in the context of the viral lytic cycle in the presence of EBV-encoded thymidine kinase (TK)/ protein...” NCT05431244 ↗
“initiating antiviral treatment with valganciclovir (900 mg every 12 hours, adjusted according to renal function as per the technical data sheet)” NCT07203664 ↗
“After prophylaxis, preemptive therapy (valganciclovir 900 mg twice daily) was indicated in both arms until month 6.” PMID 34228099 ↗Mar 2022
“secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring.” NCT03339661 ↗
“4.2.2 Valganciclovir Dosing: 16 mg/kg/dose PO q12h” NCT05564598 ↗
“The antiviral nucleoside drug, (val)ganciclovir (GCV), is effective only in the context of the viral lytic cycle in the presence of EBV-encoded thymidine kinase (TK)/ protein...” NCT05431244 ↗
Known as
NSC-760349
ChEMBL registry synonym — accepted as the source's own labelCHEMBL1201314 ↗
Known as
RO-107-9070/194
ChEMBL registry synonym — accepted as the source's own labelCHEMBL1201314 ↗
ChEMBL registry synonym — accepted as the source's own labelCHEMBL1201314 ↗
Known as
RS-79070-194
ChEMBL registry synonym — accepted as the source's own labelCHEMBL1201314 ↗
Known as
VAL
“14 days of the anti-viral Valganciclovir (VAL) to kidney donors prior to the transplant compared to placebo” NCT01329185 ↗
Known as
Valcyte
“VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients” NCT00431353 ↗10
“Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)” NCT00478465 ↗
“Valcyte (valganciclovir hydrochloride) 50 mg of valganciclovir free base per 1 mL, oral solution: given at 16.0 mg/kg, twice a day for 6 weeks.” NCT01649869 ↗
“IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients” NCT00294515 ↗
“Valcyte (valganciclovir) powder for oral solution” NCT01165580 ↗
“Combined with valganciclovir, or Valcyte(TM), it is likely to be more toxic to bone marrow.” NCT00092222 ↗
Known as
Valgan
“The study evaluated the efficacy and safety of a prolonged, continuous course of Valganciclovir (Valgan) in the prevention of CMV by comparing 3 months of Vaglanciclovir, the...” NCT00227370 ↗
Known as
Valganciclovir (as hydrochloride)
ChEMBL registry synonym — accepted as the source's own labelCHEMBL1201314 ↗
ChEMBL registry synonym — accepted as the source's own labelCHEMBL1201314 ↗
Known as
valganciclovir hydrochloride
“Valcyte (valganciclovir hydrochloride) 50 mg of valganciclovir free base per 1 mL, oral solution: given at 16.0 mg/kg, twice a day for 6 weeks.” NCT01649869 ↗4
ClinicalTrials.gov intervention name — accepted as the source's own labelNCT00078559 ↗
Known as
valGCV
“For universal prophylaxis, the antivirals most commonly used are valganciclovir (valGCV) and IV ganciclovir.” NCT03631316 ↗
Known as
VGC
“The two antiviral prophylaxis medications this study is comparing, valganciclovir (VGC) and maribavir, are highly effective at preventing CMV infection.” PMID 41018408 ↗Aug 20251
“Valganciclovir (VGC) 900 mg orally q12 hours (every 12 hours) on days 1-5 of a 14-day cycle.” NCT01441063 ↗
Known as
VGCV
“PURPOSE: To describe cytomegalovirus (CMV) end-organ disease (EOD) rate in AIDS patients with low CD4+ cell count despite HAART who were enrolled in a randomized,...” PMID 19632953 ↗May 20096
“Thirty CFS patients with elevated IgG antibody titers against HHV-6 and EBV were randomized 2:1 to receive valganciclovir (VGCV) or placebo for 6 months in a double-blind,...” PMID 23959519 ↗Aug 2013
“Treatment of solid-organ transplant (SOT) patients with ganciclovir (GCV)-valganciclovir (VGCV) according to the manufacturer's recommendations may result in over- or underexposure.” PMID 26824942 ↗Mar 2016
“900 milligrams (mg) valganciclovir (VGCV) to be taken orally once per day for 8 weeks.” NCT04724447 ↗
“Standard Treatment Ganciclovir: GCV or VGCV and SOC per local institutional practices” NCT06853184 ↗
“Specific viral encoded genes appear to convert zidovudine and ganciclovir (or valganciclovir) into toxic phosphorylated moieties within the KSHV-infected tumor cells, to...” NCT00092222 ↗
Modality
Small molecule
“The antiviral nucleoside drug, (val)ganciclovir (GCV), is effective only in the context of the viral lytic cycle in the presence of EBV-encoded thymidine kinase (TK)/ protein...” NCT05431244 ↗
Route
Oral
“Valganciclovir, an Oral Prodrug of Ganciclovir” NCT00002222 ↗